ST6GAL I MEDIATED MODULATION OF HEMATOPOIESIS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 28, 2014
app pub date -
Jun 25, 2012
filing date -
Jun 24, 2011
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (ST6Gal I). The method is suitable for prophylaxis and therapy of a condition that is positively correlated with undesirable hematopoiesis. Such conditions include autoimmune diseases, transplantation rejection, blood cancers and allergic reactions and inflammations. The invention also provides a pharmaceutical preparation that contains recombinant ST6Gal I and which is suitable for administration to an individual to reduce haematocytes in the individual, and a pharmaceutically acceptable carrier.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully